PB021

PB021 is an undisclosed biosimilar monoclonal antibody currently in the early stages of development by Polpharma Biologics Group. As of early 2024, the program is in the cell line development phase, which involves the selection and optimization of a mammalian cell line to produce the antibody with high fidelity to the reference product. While the specific biological target and the originator biologic have not been publicly identified, the candidate is being developed for a range of potential indications ('Various'). Polpharma Biologics utilizes its proprietary development platforms to ensure that biosimilars like PB021 meet stringent regulatory requirements for analytical similarity and clinical performance.